Anticoagulant News and Research

RSS
Health Canada approves AutoGenomics’ INFINITI PGx testing system

Health Canada approves AutoGenomics’ INFINITI PGx testing system

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Rensselaer Center for Stem Cell Research launches today

Rensselaer Center for Stem Cell Research launches today

New scientific findings in anticoagulation for stroke prevention

New scientific findings in anticoagulation for stroke prevention

Boehringer Ingelheim updates U.S. prescribing information for Pradaxa with FDA

Boehringer Ingelheim updates U.S. prescribing information for Pradaxa with FDA

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

FDA approves Arteriocyte’s ACD-A for use with Magellan system

FDA approves Arteriocyte’s ACD-A for use with Magellan system

Moderately higher risk of stroke for women than men with irregular heart rhythm

Moderately higher risk of stroke for women than men with irregular heart rhythm

FDA accepts CSL Behring’s 4-factor PCC BLA for standard review

FDA accepts CSL Behring’s 4-factor PCC BLA for standard review

Children with pelvic and thigh fractures rarely develop dangerous blood clots

Children with pelvic and thigh fractures rarely develop dangerous blood clots

Anti-clotting drugs rarely needed in children with big-bone fractures

Anti-clotting drugs rarely needed in children with big-bone fractures

HS6ST2 enzyme an important regulator of breast cancer cell-bone interactions

HS6ST2 enzyme an important regulator of breast cancer cell-bone interactions

Warfarin may not be as effective in elderly women with AF

Warfarin may not be as effective in elderly women with AF

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Current anticoagulant therapy to prevent stroke might not be sufficient for older women with AF

Current anticoagulant therapy to prevent stroke might not be sufficient for older women with AF

Aspirin versus warfarin for heart failure patients

Aspirin versus warfarin for heart failure patients

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

Helpful roles of rank, toxic substances

Helpful roles of rank, toxic substances

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.